Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion.
The present study evaluates the effect of ischemic preconditioning on interleukin-1 (IL-1) and interleukin-10 (IL-10) generation following hepatic ischemia/reperfusion (I/R) in normal and steatotic livers as well as the role of nitric oxide (NO) in this process. Increased IL-1beta and IL-10 levels were observed in normal livers after I/R. Steatotic livers showed higher IL-1beta levels than normal livers, and IL-10 at control levels. The injurious role of IL-1beta and the benefits of IL-10 on hepatic I/R injury was shown with the use of IL-1 receptor antagonist (IL-1ra), anti-IL-10 polyclonal antibody against IL-10 (anti-IL-10) and exogenous IL-10. The effective dose of these treatments was different in both types of livers. Preconditioning prevented IL-1beta release and increased IL-10 generation after I/R in normal and steatotic livers. IL-1beta or anti-IL-10 pretreatments reversed the benefits of preconditioning. IL-1beta action inhibition in a preconditioned group that was pretreated with anti-IL-10 did not modify the benefits of preconditioning. In addition, anti-IL-10 pretreatment in the preconditioned group resulted in IL-1beta levels comparable to those observed after I/R. NO inhibition eliminated the benefits of preconditioning on IL-10 release, IL-1beta levels, and hepatic injury. In conclusion, preconditioning, through IL-10 overproduction, inhibits IL-1beta release and the ensuing hepatic I/R injury in normal and steatotic livers. IL-10 generation induced by preconditioning could be mediated by NO.
Experimental Pathology Department, Instituto de Investigaciones Biomédicas de Barcelona-Consejo Superior de Investigaciones Cientificas, Institut d'Investigacions Biomediques August Pi i Sunyer, C/Rosello 161, 7a planta, 08036 Barcelona, Spain.
Anna
A
Serafín
Joan
J
Roselló-Catafau
Neus
N
Prats
Emilio
E
Gelpí
Joan
J
Rodés
Carmen
C
Peralta
D000818:Animals; D000906:Antibodies / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005234:Fatty Liver / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D016753:Interleukin-10 / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D019194:Ischemic Preconditioning; D008102:Liver Circulation; D009569:Nitric Oxide / Q000037:antagonists & inhibitors; D051381:Rats; D011924:Rats, Zucker; D015427:Reperfusion Injury / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D012795:Sialoglycoproteins / Q000008:administration & dosage / Q000494:pharmacology
D000906:Antibodies; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D012795:Sialoglycoproteins; D016753:Interleukin-10; D009569:Nitric Oxide